Planned publication dates for Nanoform's financial reports:

• report for Q4 2025 and full year 2025: February 26^th, 2026
• report for Q1 2026: May 19^th, 2026
• report for Q2 2026 and half-year 2026: August 20^th, 2026
• report for Q3 2026 and January-September 2026: November 11^th, 2026
• report for Q4 2026 and full year 2026: February 25^th, 2027

Nanoform plans to publish its Annual Report for the year 2025, which includes the review by the Board of Directors and the audited annual accounts, latest end of March 2026.

Nanoform’s Annual General Meeting 2026 is planned to be held April 14^th, 2026.

For further information, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com / +46 76866 50 11

About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.